US-listed UniQure shares rose 61% after the FDA cleared the company to file an application for its Huntington's disease gene therapy.

2026-06-17

US-listed UniQure shares rose 61% after the FDA cleared the company to file an application for its Huntington's disease gene therapy.

其他消息